细胞因子诱导杀伤细胞灌注治疗原发性肝癌临床应用

Cytokine-induced killer cell for interventional chemotherapy of hepatocellular carcinoma

目的探讨肝动脉细胞因子诱导杀伤细胞(CIK细胞)灌注+超液化碘油栓塞治疗原发性肝癌的疗效。方法采用超选择段性肝动脉灌注CIK细胞+超液化碘油栓塞治疗原发性肝癌及经皮肝穿刺瘤体内多点注射CIK细胞共38例(研究组);将同期采用常规剂量经肝动脉段性化疗栓塞(C-TACE)联合经皮肝瘤体内注入无水乙醇80例(双介入组);单纯经皮肝动脉常规剂量C-TACE134例(单纯组)相比较。结果研究组、双介入组和单纯组近期显效率分别为76.3%、41.3%和14.9%,研究组的AFP降至正常及明显下降率则显著高于双介入组和单纯组,3组血清AFP变化差异有统计学意义(P<0.01)。结论采用超选择段性肝动脉灌注CIK细胞+超液化碘油栓塞综合治疗原发性肝癌,可以提高患者的免疫功能、生存质量,延长带瘤生存期。

Objective To evaluate the clinical effect of hepatocellular carcinoma treatment with a combination therapy of transcather arterial super liquefied lipiodol embolization and cytokine-induced killer cell （CIK） infusion. Methods There were 3 groups in this study, group 1 ： 38 cases of HCC patients treated with a combination therapy of transcather arterial super liquified lipiodol embolization and CIK infusion; group 2： 80 cases of HCC patients treated with a combination therapy of transcather arterial super liquefied lipiodol embolization and percutaneous intratumoral ethanol injection; group 3：134 cases of HCC patient treated with transcather arterial super liquefied embolization. Finally, the outcomes of the 3 groups were compared. Results The short term effective rates of group 1,2 and 3 were 76.1%,41.3% and 14.9% respectively, simultaneously with significant difference of changes concerning AFP value among the three groups especially in group 1 the AFP decrease to normal level while those of the other two groups still remain in higher levels. Conclusions The living quality and survival rate of HCC patients could be improved by a combination therapy of transcather arterial super liquefied lipiodal embolization and CIK infusion. （J Intervent Radiol, 2007, 16： 235-239）